ActivX is a biotech company developing activity-based profiling systems for several families of drug targets (including kinases and serine hydrolases). The utility of these probes in facilitating drug discoveries has been validated for multiple therapeutic areas including metabolic diseases, oncology and pain management.
Biogazelle is a unique service provider allowing an early access to the newest instruments and cutting edge technologies for both ready-to-run experiments and customized projects. Biogazelle’s mission is to understand the transcriptome for next generation diagnostics and therapeutics through excellence in science and technology.
HyTest is a finnish biotech company offering innovative solutions for assay development and research applications, and providing high-quality immunological reagents mainly in the cardiac markers area, but also in infectious, neuroscience and autoimmune disease reagents.
HyTest – antibody development for cardiac markers
Biocrates is an internationally renowned developer of targeted metabolic phenotyping solutions, supporting the discovery and validation of biomarkers for complex multifactorial diseases.
AROS Applied Biotechnology is a leading provider of Total Genomic Solutions in Europe, covering all steps of the process, from study design, extraction, sample banking, analysis to advanced bioinformatics.
AptSci is dedicated to develop aptamer technologies to generate high quality aptamers in a wide range of applications (research, diagnosis and therapeutics). AptSci has ongoing collaboration relationships with several industry partners and is also collaborating with several universities, hospitals and research organizations.
ReadyCell is a biotech company providing sophisticated in vitro tools and R+D services for the ADME-Tox sector, including innovative cell-based and ready-to-use kits for testing of active molecules, as an alternative to animal testing. ReadyCell currently proposes a wide range of drug discovery applications for in vitro screening (metabolism, adsorption, toxicity assays, etc…).
DLVR Therapeutics is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system, initially for RNAi therapeutics.
Among advances in the field of genomic, single-nucleotide polymorphism (SNP) research has attracted a lot of attentions in recent years. SNP genotyping serves as the technological basis to understand the causes of diseases at the genetic level, and is very useful for pharmacogenomic researchers. In order to establish a certain path to the realization of personalized medicine, Riken Genesis is using state-of-the-art technology to explore a total of 6 billion base pairs.
Biocon, India’s largest biotech company, is focused on delivering affordable innovation by leveraging India’s cost advantage to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.
